Department of Peri-operative Medicine and Anaesthesia, Torbay Hospital, Torquay, UK.
Department of Intensive Care Medicine, Torbay Hospital, Torquay, UK.
Anaesthesia. 2021 Apr;76(4):472-479. doi: 10.1111/anae.15263. Epub 2020 Oct 11.
Concerned that studies contain false data, I analysed the baseline summary data of randomised controlled trials when they were submitted to Anaesthesia from February 2017 to March 2020. I categorised trials with false data as 'zombie' if I thought that the trial was fatally flawed. I analysed 526 submitted trials: 73 (14%) had false data and 43 (8%) I categorised zombie. Individual patient data increased detection of false data and categorisation of trials as zombie compared with trials without individual patient data: 67/153 (44%) false vs. 6/373 (2%) false; and 40/153 (26%) zombie vs. 3/373 (1%) zombie, respectively. The analysis of individual patient data was independently associated with false data (odds ratio (95% credible interval) 47 (17-144); p = 1.3 × 10 ) and zombie trials (odds ratio (95% credible interval) 79 (19-384); p = 5.6 × 10 ). Authors from five countries submitted the majority of trials: China 96 (18%); South Korea 87 (17%); India 44 (8%); Japan 35 (7%); and Egypt 32 (6%). I identified trials with false data and in turn categorised trials zombie for: 27/56 (48%) and 20/56 (36%) Chinese trials; 7/22 (32%) and 1/22 (5%) South Korean trials; 8/13 (62%) and 6/13 (46%) Indian trials; 2/11 (18%) and 2/11 (18%) Japanese trials; and 9/10 (90%) and 7/10 (70%) Egyptian trials, respectively. The review of individual patient data of submitted randomised controlled trials revealed false data in 44%. I think journals should assume that all submitted papers are potentially flawed and editors should review individual patient data before publishing randomised controlled trials.
我担心研究中包含虚假数据,因此分析了 2017 年 2 月至 2020 年 3 月提交给《麻醉学》的随机对照试验的基线汇总数据。如果我认为试验存在致命缺陷,我将包含虚假数据的试验归类为“僵尸”。我分析了 526 份提交的试验:其中 73 份(14%)存在虚假数据,43 份(8%)被归类为僵尸。与没有个体患者数据的试验相比,个体患者数据增加了对虚假数据的检测和对试验的归类为僵尸:67/153(44%)为假 vs. 6/373(2%)为假;40/153(26%)为僵尸 vs. 3/373(1%)为僵尸,分别。个体患者数据的分析与虚假数据(比值比(95%可信区间)47(17-144);p=1.3×10)和僵尸试验(比值比(95%可信区间)79(19-384);p=5.6×10)独立相关。来自五个国家的作者提交了大部分试验:中国 96 项(18%);韩国 87 项(17%);印度 44 项(8%);日本 35 项(7%);埃及 32 项(6%)。我确定了包含虚假数据的试验,并依次将试验归类为僵尸:27/56(48%)和 20/56(36%)中国试验;7/22(32%)和 1/22(5%)韩国试验;8/13(62%)和 6/13(46%)印度试验;2/11(18%)和 2/11(18%)日本试验;9/10(90%)和 7/10(70%)埃及试验,分别。对提交的随机对照试验的个体患者数据的审查显示,44%的试验存在虚假数据。我认为期刊应该假设所有提交的论文都可能存在缺陷,编辑应该在发表随机对照试验之前审查个体患者数据。